Clinical Scorecard: Glaucoma Neuroprotection: Still Searching for the Right Notes
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Glaucoma Neuroprotection |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | The article discusses preclinical and human nicotinamide evidence, observational GLP-1 receptor agonist studies in patients with diabetes and people using these agents for weight management, and potential relevance to glaucoma. |
| Care Setting | A presentation at AAO 2026 Glaucoma Subspecialty Day reviewed nicotinamide and GLP-1 receptor agonists as potential neuroprotective approaches. |
Key Highlights
- Preclinical studies found that nicotinamide increased NAD levels and prevented glaucomatous damage in mice; early human studies suggested functional benefits.
- The article describes uncertainty in interpreting small changes in PhNR and individual visual field locations because these measures are variable.
- A prospective Hong Kong trial of nicotinamide riboside found no protective effect against glaucoma progression; outcomes among older participants were potentially worse.
- Retrospective studies associated GLP-1 receptor agonist use with lower glaucoma rates, but cannot establish causality or show protection against progression in established glaucoma.
- The presenter said he does not routinely recommend either treatment and called for randomized controlled trial evidence.
Guideline-Based Recommendations
Diagnosis
Management
- Presenter's view: Dr. Welsbie said he does not routinely recommend nicotinamide while awaiting randomized controlled trial results.
- Presenter's view: Dr. Welsbie said he does not yet routinely recommend GLP-1 receptor agonists for glaucoma neuroprotection and said a randomized controlled trial is needed.
Monitoring & Follow-up
- The article reports that high-dose nicotinamide has been associated with hepatotoxicity.
- The article reports an association between GLP-1 receptor agonists and NAION, described as rare.
Risks
- Dr. Welsbie emphasized distinguishing nicotinamide from niacin, which he described as having a worse toxicity profile.
- PhNR and individual Humphrey 24-2 visual field test locations are subject to considerable measurement variability.
- Observational GLP-1 receptor agonist studies cannot establish causality or demonstrate reduced progression in established glaucoma.
Patient & Prescribing Data
Evidence discussed includes preclinical and human nicotinamide studies, observational GLP-1 receptor agonist studies in patients with diabetes, and studies of people using these agents for weight management.
Dr. Welsbie said he does not routinely recommend nicotinamide or GLP-1 receptor agonists for glaucoma neuroprotection. The article reports hepatotoxicity associated with high-dose nicotinamide and an association between GLP-1 receptor agonists and rare NAION; GLP-1 evidence described is observational.
Clinical Best Practices
- Dr. Welsbie cautioned that small changes in PhNR and individual visual field locations are difficult to interpret because of measurement variability.
- Dr. Welsbie cautioned that observational associations between GLP-1 receptor agonist use and lower glaucoma rates do not establish causality or protection against progression.
- Dr. Welsbie emphasized distinguishing nicotinamide from niacin because he described niacin as having a worse toxicity profile.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.